Spero Oncology

Bellshill, United Kingdom Founded: 2014 • Age: 12 yrs Acquired By Veristat
Clinical operations support is provided for oncology trials.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About Spero Oncology

Spero Oncology is a company based in Bellshill (United Kingdom) founded in 2014 was acquired by Veristat in May 2016. Spero Oncology operates in a competitive market with competitors including Helsinn, Aster Insights, CancerVax, Abogen Biosciences and OnCusp, among others.

  • Headquarter Bellshill, United Kingdom
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    Not available
  • Acquired by
    Veristat

    (May 01, 2016)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Spero Oncology

Premium access

Detailed funding history for Spero Oncology

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in Spero Oncology

Spero Oncology has secured backing from 1 investor. Prominent investors backing the company include Veristat.

All
Investor Description Founded Year Domain Location
Clinical trials and regulatory submissions are supported as a CRO.
Locked Locked Locked
Premium access

Investor details for Spero Oncology

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Spero Oncology

Investments
Premium access

Investment portfolio details for Spero Oncology

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Spero Oncology

Premium access

Detailed financials for Spero Oncology

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Spero Oncology Comparisons

Spero Oncology Primary company
Description
Clinical operations support is provided for oncology trials.
Location
Bellshill, United Kingdom
Founded Year
2014
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Spero Oncology

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Spero Oncology

Spero Oncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Helsinn, Aster Insights, CancerVax, Abogen Biosciences and OnCusp, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Oncology therapeutics are developed, manufactured, and commercialized by Helsinn.
Locked Locked Locked
Contract-based oncology clinical trial services are provided by Aster Insights.
Locked Locked Locked
Cancer vaccine research and development is conducted by CancerVax.
Locked Locked Locked
mRNA-based therapeutics are developed for cancer and infectious diseases.
Locked Locked Locked
CRO offering clinical development services for oncology drugs
Locked Locked Locked
Preclinical and clinical oncology drug development services are provided.
Premium access

Detailed competitors of Spero Oncology

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Spero Oncology

Premium access

Complete news archive for Spero Oncology

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Spero Oncology

Spero Oncology was founded in 2014.

Spero Oncology is headquartered in Bellshill, United Kingdom. It is registered at Bellshill, Scotland, United Kingdom.

Spero Oncology was established in 2014 in Bellshill, United Kingdom, as a contract research organization focused on the oncology sector. Clinical operations support is delivered for oncology trials, encompassing feasibility studies, legal representation in the European Union, clinical monitoring, project management, protocol writing, and regulatory strategy. Services are extended primarily across Europe, Australia, and New Zealand. The organization was acquired by U.S.-based CRO Veristat for an undisclosed amount.

Spero Oncology's top competitors include Helsinn, CancerVax and OnCusp.

Spero Oncology has 1 investor. Key investors include Veristat.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available